| Elizabeth A Miller, PT | |
|
3385 Dexter Ct, Ste 301, Davenport, IA 52807-3494 | |
| (563) 344-6645 | |
| (563) 441-7796 |
| Full Name | Elizabeth A Miller |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 14 Years |
| Location | 3385 Dexter Ct, Davenport, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043516073 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 004706 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopaedic Specialists Pc | 9931090875 | 19 |
News Archive
Researchers from the University of Pennsylvania School of Veterinary Medicine have discovered that a protein called Jagged-1 stimulates human stem cells to differentiate into bone-producing cells.
Disease-modifying antirheumatic drugs should be used early and aggressively at the first sign of rheumatoid arthritis. The results of an 11-year trial, published in BioMed Central's open access journal Arthritis Research & Therapy, demonstrate that active treatment from the very beginning pays off, even in the long run.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.
People who carry a particular genetic variant are at significantly increased risk of developing malignant melanoma, new research shows.
› Verified 9 days ago
| Provider Name | Orthopaedic Specialists Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1831168764 PECOS PAC ID: 9931090875 Enrollment ID: O20040322000988 |
News Archive
Researchers from the University of Pennsylvania School of Veterinary Medicine have discovered that a protein called Jagged-1 stimulates human stem cells to differentiate into bone-producing cells.
Disease-modifying antirheumatic drugs should be used early and aggressively at the first sign of rheumatoid arthritis. The results of an 11-year trial, published in BioMed Central's open access journal Arthritis Research & Therapy, demonstrate that active treatment from the very beginning pays off, even in the long run.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.
People who carry a particular genetic variant are at significantly increased risk of developing malignant melanoma, new research shows.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth A Miller, PT 3385 Dexter Ct, Ste 301, Davenport, IA 52807-3494 Ph: (563) 344-6645 | Elizabeth A Miller, PT 3385 Dexter Ct, Ste 301, Davenport, IA 52807-3494 Ph: (563) 344-6645 |
News Archive
Researchers from the University of Pennsylvania School of Veterinary Medicine have discovered that a protein called Jagged-1 stimulates human stem cells to differentiate into bone-producing cells.
Disease-modifying antirheumatic drugs should be used early and aggressively at the first sign of rheumatoid arthritis. The results of an 11-year trial, published in BioMed Central's open access journal Arthritis Research & Therapy, demonstrate that active treatment from the very beginning pays off, even in the long run.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.
People who carry a particular genetic variant are at significantly increased risk of developing malignant melanoma, new research shows.
› Verified 9 days ago
Muna Majdi Omar, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 5254 Utica Ridge Rd, Davenport, IA 52807 Phone: 563-359-3799 | |
Ms. Sara Katherine Petersen, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1008 W 35th St, Davenport, IA 52806 Phone: 563-362-0060 | |
Joel D Mason, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3385 Dexter Ct, Plaza Physical Therapy, Davenport, IA 52807 Phone: 563-344-6645 Fax: 563-441-7796 | |
Quad City Physical Therapy & Spine Physical Therapist Medicare: Medicare Enrolled Practice Location: 5254 Utica Ridge Rd, Davenport, IA 52807 Phone: 563-359-3799 Fax: 563-359-3804 | |
Mr. Michael Leonard Puthoff, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 518 W Locust St, Physical Therapy Department, Davenport, IA 52803 Phone: 563-333-6009 | |
Randall E Boldt, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1008 W 35th St, Davenport, IA 52806 Phone: 563-324-2263 Fax: 563-324-0719 |